Highlight
Summary
About the Role
About You
- 2+ years of accounts payable experience.
- Associate or Bachelor’s degree in Accounting, Finance or related field, or equivalent professional experience.
- Proficiency with NetSuite or similar ERP systems.
- Understanding of AP processes and internal controls.
- Excellent attention to detail and organizational skills.
- Strong communication and interpersonal abilities.
- Ability to work in a fast-paced environment and handle multiple tasks.
- Proven mindset of proactive continuous improvement.
- Efficient independent worker with ability to focus and drive for results.
- Strong commitment to ethical standards.
- Proficient with Microsoft Office suite (i.e., Word, PowerPoint, Excel, Outlook, SharePoint, etc.).
Benefits
- Competitive pay and stock options for all employees.
- Medical, dental, and vision coverage with 100% of premiums paid by Viridian for employees and their eligible dependents.
- Fertility and mental health programs.
- Short- and long-term disability coverage.
- Life, Travel and AD&D insurance.
- 401(k) Company Match with immediate company vest.
- Employee Stock Purchase plan.
- Generous vacation plan and paid company holiday shutdowns.
- Various mental, financial, and proactive physical health programs covered by Viridian.
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.